G9pharma co., LTD reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was KRW 5,121.42 million compared to KRW 7,679.5 million a year ago. Basic loss per share from continuing operations was KRW 1,256 compared to KRW 2,227 a year ago. Basic loss per share was KRW 1,256 compared to KRW 2,227 a year ago.